Abstract Kigamicin D did not show any immunosuppressive activity in mixed lymphocyte culture reaction and mitogen induced lymphocyte blastogenesis in vitro and graft versus host reaction in vivo. Natural killer cell activity in spleen cells was not affected by oral administration of kigamicin D. Instead, delayed-type hypersensitivity response to sheep red blood cells was stimulated at a broad dosage level. It is concluded that kigamicin D increases cellular immunity to specific antigen.
(2ϫ10 5 ) taken from C 3 H/He mice (8ϳ12 weeks old, H-2 k ) and passed through a nylon wool column were used as a responder. As stimulator cells, spleen cells (2ϫ10 5 ) were taken from BALB/c mice (8ϳ12 weeks old, H-2 d ) and treated with mitomycin C at 37°C for 20 minutes. Responder cells and stimulator cells were mixed and cultured for 72 hours with kigamicin D, Con A and/or LPS. Kigamicin D was dissolved in DMSO (10 mg/ml) as a stock solution and diluted with PBS just before use. The culture was pulsed with 0.5 mCi per well of 3 H-thymidine 16 hours before assay, followed by counting incorporated 3 H-thymidine into the cells with a Packard matrix 9600 beta-counter apparatus.
Mitogen Induced Lymphocyte Blastogenesis
Lymphocyte blastogenesis was examined by the method described previously [6] . Murine spleen cells (1ϫ10 6 /ml) were cultured for 72 hours with Con A (0.5 mg/ml) or LPS (2.0 mg/ml) in the various concentrations of kigamicin D. Antiproliferation activities were examined by measuring the incorporation of 3 H-thymidine as in the case of MLCR.
Graft Versus Host Reaction (GvHR)
GvHR was induced by the method of Ford et al. [7] . Spleen cells used as the graft were taken from adult C57BL/6 mice and injected into the right footpad of 7-day-old BDF 1 mice in an inoculum form of 10 7 cells/50 ml. Kigamicin D was orally administered once daily for 5 days from the next day after inoculation of the allogenic spleen cells. As a positive control, 15-deoxyspergualin (DSG, saline solution) was intraperitoneally administered according to the same schedule as kigamicin D. Seven days later, the mice were sacrificed and popliteal lymph nodes were removed from both extremities. Lymph node weights were measured. Enlargement in lymph nodes was calculated as a difference between the popliteal lymph node weight of right (injected) leg and that of left (uninjected) leg.
NK Cells Activity
Spleen cells from BDF 1 mice that had received daily oral administration of kigamicin D and cytostatin (CTS) for 3 days, were prepared and NK cells activity was examined. CTS (2.5 mg/kg) was administered intraperitoneally as a positive control. One day after the last treatment, spleen cells were prepared. NK cytolytic activity was performed by a modification of calcein-AM assay as previously described in detail [8] . Briefly, spleen cells obtained from mice were used as effector cells. YAC-1 cells labeled with 10 mg/ml of calcein-AM were used as target cells. Labeled YAC-1 cells (0.1 ml, 2ϫ10 4 cells) and effector cells (0.1 ml) were added to each well of a 96-well plate to produce various effector-to-target (E/T) ratios. This plate was incubated for 4 hours at 37°C. Fluorescence of cell-free supernatant (0.1 ml from each well) after centrifugation was measured via a spectrofluorometer (Labsystems Fluoroscan II; Dainippon Seiyaku, Osaka, Japan), using an excitation of 475 nm and an emission of 538 nm. Cytolytic activity (as % lysis) was calculated by the following formula: % of specific lysisϭ(EϪS)/ (MϪS)ϫ100 (where E is fluorescence in experimental cultures; S is the spontaneous fluorescence released in cultures containing target cells alone; M is the maximum fluorescence obtained by lysing all cells with 0.5% Triton X-100.
Delayed-type Hypersensitivity (DTH)
DTH to sheep red blood cells (SRBC) was performed according to the method described previously [9] . Female 13-weeks-old CDF 1 mice were immunized by intravenous injection of 10 5 SRBC (0.1 ml, saline). Kigamicin D and bestatin (saline solution) as a positive control, were orally administered daily for 4 days starting from the day of immunization. An immunosuppressant, DSG (saline solution) was intraperitoneally administered according to the same schedule as kigamicin D. Four days after immunization, DTH response was elicited by subcutaneous injection of 10 8 SRBC (50 ml, saline) to the footpad, and 24 hours later, the footpad thickness was measured with a caliper. Footpad swelling was obtained by subtracting mean footpad thickness of normal mice from those of each DTH group (nϭ5).
Statistical Analysis
All results were expressed as meansϮS.D. Statistical comparisons were made using Student's t test after analysis of variance. The results were considered to be significantly different if P value Ͻ0.05.
Results and Discussion

MLCR
As shown in Table 1 , kigamicin D did not inhibit MLCR, but 0.049 m g/ml showed statistically significant (pϽ0.01) elevation of MLCR to control (168%). Higher concentration above 0.195 mg/ml showed cytotoxicity.
Mitogen Induced Lymphocyte Blastogenesis
As shown in Table 2 , kigamicin D did not show mitogenic activity on spleen cells by itself. It did not show any effect on Con A or LPS induced blastogenesis unlike PMA.
GvHR
As shown in Table 3 , kigamicin D did not show any effect on GvHR.
NK Cells Activity
NK cells play an important role in immune surveillance against tumor development. Effect on NK cells activity was evaluated by a modified calcein-AM assay. As shown in Fig. 1 , spleen cells from mice administered orally by kigamicin D showed the same NK activity as spleen cells from non-treated mice, while CTS [10] treated as a positive control, significantly augmented NK activity.
DTH
The results above mentioned show kigamicin D has no mitogenic activity such as bestatin and swainsonine, and immunosuppressive activity such as DSG. Kigamicin D does not have direct effect on T, B, and NK lymphocytes. From our observation that the site of administration in the case of intravenous treatment became hardened and swollen, we examined effect of kigamicin D on antigen specific immune response. As shown in Fig. 2 administration of kigamicin D augmented DTH response at doses from 0.012 to 0.188 mg/kg. The activity was beyond bestatin.
As described elsewhere, we determined that interferon g and TNF-a were highly induced in spleen cells from mice administered oral kigamicin D, and IL-12 production in dendritic cells was induced by kigamicin D in vitro. The augmentation of the cellular immunity was suggested to be caused by activation of dendritic cells (DCs) by kigamicin D. Moreover, kigamicin D increased IL-6 production induced by LPS in P388D1 cells, a macrophage cell line in vitro (to be published elsewhere). Thus the target cells of kigamicin D in immune response seemed to be antigen presenting cells such as DCs and macrophages.
The signal transduction mechanism of how kigamicin D shows effect on antigen presenting cells may be related to inhibition of PI3K/Akt pathway by kigamicin D under nutrient deprived condition. Fukuo T. and Koyasu S. [11] have shown that PI3K is an endogenous suppressor of IL-12 production and Th1 dominant immune response, in studies of the immune response of p85a regulatory subunit of class IA PI3K knockout mice and IL-12 production from DCs in vitro by wortmannin, a PI3K inhibitor. Kigamicin D inhibits PI3K/Akt pathway as previously described [2] and PI3K inhibitors such as wortmannin and LY294002 showed the same activity inhibiting cancer cell viability preferentially during nutrient starvation like kigamicin D [2, 12] . Kigamicin D showed antiangiogenic activity [4] like PI3K inhibitors and induced IL-12 production from DCs in vitro as described elsewhere.
DCs, powerful antigen presenting cells capable of inducing primary T cell responses in vitro and in vivo has recently generated widespread interest in DC-based immunotherapy of several human malignancies. Kigamicin D which acts on DCs may be useful for eliciting stronger antigen recognition and cytotoxic T cells response. 
